What does this research mean for the field?

Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

August 27, 2021New England Journal of MedicineOpen Access

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

View Full Paper

Ask AI

Bookmark

Key result

Empagliflozin lowered the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and preserved ejection fraction, regardless of diabetes status.

Authors

SAStefan D. AnkerBrigham and Women's Hospital

Javed ButlerHeart Failure / Cardiomyopathy

Gerasimos FilippatosNorthwestern University

Discussion

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Anker et al. (2021) studied this question. Empagliflozin lowered the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and preserved ejection fraction, regardless of diabetes status.

synapsesocial.com/papers/6973c8fc4850f876c58a3ef3 https://doi.org/10.1056/nejmoa2107038

View Full Paper

Ask AI

Bookmark

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Discussion

Member takes

Implication

Key Points

Cite This Study

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider